



2021 PORTUGAL.EU

Porto Declaration on Cancer Research

Porto, 3 May 2021

PORTO DECLARATION ON CANCER RESEARCH

Open to be signed by citizens and institutions as a result of the Cancer Research Summit 2021, Porto, 3rd May 2021

The undersigned call for a collective action throughout Europe towards a comprehensive translational cancer research approach focused on personalized and precision medicine and covering the entire cancer research continuum, from prevention to care. This requires specific actions to strengthen a network of well distributed and interconnected high-quality infrastructures for translational research, clinical and prevention trials and outcomes research, to ensure that science-driven and social innovations benefit patients and individuals at risk across the healthcare systems in the European Union (EU).

We consider that such a European-wide deployment of high-quality infrastructures has the potential to achieve in 2030 a 10-year cancer-specific survival for 75% of patients diagnosed in EU member states with a well-developed healthcare system.

This target is critically important because cancer is one of the major health problems affecting our society, a situation that is set to deteriorate globally as the population grows and ages. The yearly burden of cancer is expected to increase in the EU member states from the current 3.5 million to more than 4.3 million by 2035. Over this period, the number of individuals that live with a cancer diagnosis during and after treatment and may require regular screening and specialized care, including rehabilitation and psychological and socio-economic support, will rise even steeper.

We, therefore, consider that the fight against cancer will be more successful if Europe relies on a shared network that acts in concert and hence call on all EU member states to strengthen and further develop their existing national initiatives in the areas of prevention, early detection, diagnosis, treatment and long-term follow-up or support.

Under this context, the **Cancer Research Summit 2021**, organized by the Portuguese Presidency of the EU in collaboration with the European Commission, focused on key aspects of cancer research that are essential for the successful implementation of the *Europe's Beating Cancer Plan* and *Europe's Cancer Mission* goals established under the Horizon Europe Program for 2021-27.

The Summit followed the Declaration on effective cancer research **“Europe United against Cancer”** signed on October 13, 2020, by Germany, Portugal and Slovenia, under the EU Council Presidency Trio in order to guide future directions for research and related links with the health systems throughout Europe.

Reducing the increased cancer burden will require the implementation of concerted actions covering the whole cancer research/care/prevention continuum, spanning from basic and preclinical research through clinical and prevention research to outcomes research. Further,

research must cover all components of cancer therapeutics/care and prevention with active citizen/patient participation in the full translational cycle from research to patient care or disease prevention, ensuring that the patient is at the centre of shared decision-making.

Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, as well as the establishment of high-quality networked infrastructures will pave the way not only to clinical innovation, but also to the mitigation of economic and social inequalities across European countries. This requires strengthening the following network of distributed and interconnected high-quality infrastructures for translational research, clinical research, and outcomes research.

These three infrastructures all cohere and are integrated in well-known infrastructures in Europe – the Comprehensive Cancer Centres (CCCs). These CCCs have the multidisciplinary expertise, capacity and integration of clinical care, research, education, samples, data, trials and core facilities to be the major engine rooms of progress in these three areas of activity. They perform according to international standards set by OECD and German Cancer Aid (for Germany) and EACS intends to expand its Designation of Research Excellence to those with the most leading-edge science. Thus they represent an existing accredited and networked foundation for the aims of the Cancer Mission and Europe's Beating Cancer Plan.

We urge Member States to use this existing network as a foundation, and commission appropriate consulting expertise to develop new CCCs (10 Member States lack them) and develop networks of care and research around CCCs – to meet the following three infrastructure needs.

1. Infrastructures for translational research:

Translational research bridges basic/preclinical research with clinical and prevention research and builds on inventions and innovations from basic/preclinical research to directly impact therapeutic and prevention research. Complex and advanced infrastructures are required to bridge with healthcare (Comprehensive Cancer Centres).

Molecular and digital pathology is essential for stratifying patients for systemic treatment with anticancer agents and liquid biopsies are being implemented as a complementary diagnostic/monitoring tool. Infrastructure support is also increasing in complexity for radiation and surgical therapy, imaging and immunotherapy. Identification of relevant early tumor lesions for prevention is a strategic research area. The collection of treatment and biological data combined with biobanking provide infrastructures for bidirectional translational research and computational science.

Consortia of advanced CCCs linked to basic/preclinical research are needed, and Cancer Core Europe is the first example of such a consortium. With successful proof of principle clinical/prevention trials, translation will continue by means of clinical research to achieve effective healthcare system implementation and reducing the time spanning from scientific discovery to patient benefit.

2. Infrastructures for clinical and prevention trials:

'Proof-of-concept' studies may serve as a starting point for further clinical and prevention research, with a practice-changing aim, including the assessment of its utility in healthcare or prevention, patients'/individuals 'at risk, cure/survival and health-related quality of life. Well-developed clinical trial structures, and advanced diagnostic methods such as state-of-the-art molecular pathology, omics technologies, and pharmacology to stratify patients as well as innovative imaging are crucial. CCCs can play a role in this together with clinical research networks. The European Organisation for Research and Treatment of Cancer (EORTC) can facilitate this.

For prevention, infrastructures must include strong epidemiology closely connected to basic research, data acquisition capacity, and advanced computational capabilities, and both the International Agency for Research on Cancer (IARC) and Cancer Prevention Europe can play a prominent role in this, along with many other stakeholders. Again, it will be critical to establish funding mechanisms that stimulate these activities and guarantee sustainability. Funding should include resources for proof-of-concept trials initiated by academic investigators.

3. Infrastructures for outcomes research:

Evidence of the effectiveness of therapeutics and prevention strategies is essential for the assessment of clinical utility, cost-effectiveness, accessibility, sustainability and prioritization. Outcomes research in therapeutics addresses questions related to all aspects of the clinical pathway, including treatment optimization, side effects of treatments, long-term follow-up with assessment of health-related quality of life, rehabilitation and survivorship, as well as attention to social and economic aspects. This should preferably be a collaborative effort between clinicians, researchers and epidemiologists. For prevention, outcomes can be measured using data from population-based registries for cancer incidence and mortality.

The European Commission's new Knowledge Centre on Cancer will also help foster scientific and technical alignment, coordination and support of European actions against cancer. The Knowledge Centre provides the European Cancer Information System, the European Guidelines and Quality Assurance Schemes for Breast, Colorectal and Cervical cancers and European Best Practices on cancer prevention through its Health Promotion and Disease Prevention Knowledge Gateway.

Indeed, it should become standard that all patients within the European Union have access to state-of-the-art cancer prevention, diagnostics, treatment, and aftercare procedures, regardless of where they live. Comprehensive Cancer Centres and CCC-like entities working in networks (or consortia) are ensuring that this happens today in many European regions by developing

treatments tailored to the patients' individual needs based on the latest scientific findings, put forward by the European Code of Cancer Practice.

By further developing, involving and enlarging CCCs and networks throughout all of Europe it will facilitate access to the infrastructures described above and will provide researchers with access to the required critical mass of patients, multidisciplinary expertise, biological materials, technological resources, data, and collaborative projects. Furthermore, they will bridge research with the healthcare systems.

The seeming inequalities both within and among EU Member States regarding prevention and treatment as well as care and prevention, require more efficient and adaptable funding mechanisms. Synergies amongst regional, national, and European funding mechanisms should therefore be pursued to facilitate access to these important networks of distributed and interconnected high-quality infrastructures.

Coordinated efforts across the European Union are thus required as no country can succeed on its own on the fight to beat cancer. Hence, we endorse the call for European-wide mobilization of well distributed, interconnected high-quality infrastructures for translational research, clinical and prevention trials, and outcomes research ensuring that science-driven and social innovations benefit patients and individuals at risk across the healthcare systems in the European Union.

Porto, 3rd of May 2021

Manuel Heitor, Minister of Science, Technology and Higher Education, Portugal

Marta Temido, Minister of Health, Portugal

Julio Celis, Associated Scientific Director, Danish Cancer Society Research Center, Denmark

Ulrik Ringborg, Director, Cancer Center Karolinska, Sweden

Anton Berns, President, European Academy of Cancer Sciences & Netherlands Cancer Institute (NKI), Netherlands

Michael Bauman, Chairman and Scientific Director, German Cancer Research Centre (DKFZ), Germany

Joachim Schüz, Head of Research Branch, International Agency for Research on Cancer (IARC/WHO), France

Fátima Cardoso, Director of the Breast Unit, Champalimaud Clinical Center, Portugal

Fátima Carneiro, Professor & Senior Researcher, Faculty of Medicine - University of Porto & Ipatimup/i3S, Portugal

Matti Aapro, President, European Cancer Organization (ECCO), Belgium

ECCO - European Cancer Organization

Françoise Meunier, Vice-president, Belgian Royal Academy of Medicine & Federation of European Academy of Medicine

José Carlos Machado, Member of the Board of Directors, Institute for Investigation and Innovation In Health (I3S), Portugal

Jan Korbel, Head of Data Science, European Molecular Biology Laboratory (EMBL), Germany

Denis Lacombe, Director General, European Organisation for Research and Treatment of Cancer (EORTC), Belgium

Jose Martin-Moreno, Professor, Clinical Hospital and Medical School, University of Valencia, Spain

Péter Nagy, Scientific Director, National Institute of Oncology, Magyarország

Rui Henrique, Chairman, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Marta Soares, Clinical Director, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Manuel Teixeira, Director of Research Center, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Rui Medeiros, President, ECL European Association of Cancer Leagues

Jelena Roganovic, Clinical Hospital Center Rijeka, Croatia

Lúcio Lara Santos, Surgeon and Researcher, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Júlio Oliveira, Medical Oncologist and Researcher, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Patrícia Calado, Member of the Board, AICIB - Agência de Investigação Clínica e Inovação Biomédica, Portugal

Carmen Jerónimo, Researcher, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Bianca Troncarelli, Junior Researcher, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

João Lobo, Medical resident and PhD student, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Olli Kallioniemi, Professor and Director, SciLifeLab, Karolinska Institutet, Science for Life Laboratory

Sara Monteiro-Reis, Post-doctoral fellow, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Sofia Salta, PhD student, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Filipa Moreira Silva, Research assistant, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Ariane Falconi, Research Technician, AC Camargo Cancer Center, Brazil

Margareta Correia, Researcher, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Simon J Oberst, Chair, Accreditation Board, European Organization of Cancer Institutes (OEI), Belgium

Claudia Martins de Lima, PhD student, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Kathi Apostolidis, President, Hellenic Cancer Federation - ELLOK, Greece

Vera Miranda Gonçalves, Junior Researcher, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Cecília Moura, Dermatologist, Instituto Português de Oncologia de Lisboa, Portugal

Catarina Macedo Silva, PhD student, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Mary Rive, Journalist, France

Vera Constâncio, PhD student, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Ana Rita Marques, MSc student, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Hein Van Poppel, Adjunct Secretary General, European Association of Urology, Netherlands

Francesco De Lorenzo, President, Italian Federation of Cancer Patient Organizations, Italy

Rui Amaral Mendes, Researcher and Adjunct Professor, CINTESIS and Case Western Reserve University, Portugal and USA

Joana Liz Pimenta, Resident in Medical Oncology, Centro Hospitalar de Trás os Montes e Alto Douro, Portugal

Filipa Reis, MSc student, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

Marek Svobod, General Director, Masaryk Memorial Cancer Institute, Czech Republic

José Pedro Sequeira, MSc student, Portuguese Oncology Institute of Porto (IPO Porto), Portugal

OECI - Organization of European Cancer Institutes

DIGICORE - Digital Institute of Cancer Outcomes Research

Isabel Mesquita, PhD student, I3s, CHUP, Portugal

Raquel Almeida, Principal Researcher, Ipatimup/i3S, Portugal

Maria Inês Clara, PhD student, University of Coimbra, Portugal

António Taveira Gomes, Presidente do Conselho de Administração, ULS Matosinhos, Portugal

Joana Peixoto, PhD student, i3S-Ipatimup, Portugal

Cátia Magalhães, Clinical Trials Manager, Roche Farmacêutica Química, Portugal

Luis Araújo, Diretor, IPO PORTO, Portugal

Celso Reis, Principal Research; Group Leader, i3S/IPATIMUP/University of Porto, Portugal

Rui Sousa Martins, Biology Student, University of Porto, Portugal

Renata Freitas, Investigator, I3S, Portugal

Rute Salomé da Silva Pereira, Registered nurse, IPO Porto; ICBAS-UP; ESEP, Portugal

Diana Montezuma Felizardo, Pathologist; PhD student, IMP Diagnostics; IPO Porto, Portugal

Luisa Pereira, Senior Researcher, i3S, Portugal

Berta Reis, Study Nurse, IPO Porto, Portugal

José Ricardo de Almeida Luís, Portfolio & Partnership Manager, Roche, Portugal

Bárbara Peleteiro, Cancer epidemiologist, Centro Hospitalar Universitário São João, Portugal

Silvia Socorro, Full Professor, CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Portugal

Meriem Lamghari, Principal Investigator- Group leader-Neuro-skeletal Circuits, i3S, Portugal

Nuno Ribeiro, Junior researcher, Ipatimup/i3S, Portugal

Manuela Babo, Nurse, IPO Porto, Portugal

Ana Simões, PhD student, Fundación Instituto de Investigación Sanitaria Santiago de Comspotela, Spain

Aníbal de Figueiredo Santos, Senior Key Account Manager, Eisai Farmacêutica Lda, Portugal

Ana Margarida Inácio Veloso, Master student, FCUL, Portugal

Sandra Sarmento, Medical Physicist, IPO Porto, Portugal

Carla Campos, Student, IPO Porto, Portugal

Ricardo João da Silva Guimarães Pinto Lopes, Técnico Superior de Diagnóstico e Terapêutica Farmácia. IPO Porto, Portugal

Lukas Plank, Prof. M.D., Ph.D., Chairman, Department of Pathology, Comenius University Jessenius Medical Faculty in Martin, Slovakia, Slovensko

Carmen Filipa Ribeiro Dias Carneiro, Clinical Director, Centro Hospitalar Tâmega-Sousa , EPE, Portugal

Ana Paula Santos, Endocrinology Consultant, Clinical Researcher, IPO Porto, Portugal

Jorge Gonçalves, Professor & Senior Researcher, Faculty of Pharmacy & i3S, University of Porto, Portugal

Rui Vasco Simões, Postdoc, Champalimaud Foundation, Portugal

Mário Dinis-Ribeiro, Diretor, Serviço de Gastrenterologia, IPO Porto, Portugal

Sara Cruz, Enfermeira, IPO Porto, Portugal

Andrada Ianus, Researcher, Champalimaud Foundation, Portugal

Salomé Pinho, Principal Investigator, Institute for Research and Innovation in Health (i3S), University of Porto, Portugal

Ken Mastris, President of ECPC, European Cancer Patient Coalition, Portugal

Maja Cemazar, Head of Research and Education, Institute of Oncology Ljubljana, Slovenia

Sónia Maria Almeida Guedes de Melo, Researcher, i3S Institute for Research and Innovation in Health, Portugal

Dulce Maria Gonçalves Pereira, Enfermeira Especialista Médico Cirúrgica, Hospital São João, Portugal

Luis Filipe dos Santos Silva, Director - Public Awareness of Cancer Unit, IPATIMUP-i3S, Portugal

Hugo Duarte, Head of Nuclear Medicine Department, IPO Porto, Portugal

Marina Andrea Marques Borges, Diretora Serviço de Planeamento e Apoio à Gestão, IPO Porto, Portugal

Bárbara Adélia Meireles Barbosa, Radiation Therapist and Researcher, IPO Porto, Portugal

Daniela Pereira, Researcher, Champalimaud Research, Portugal

Sandra F. Gomes, PhD student, Faculty of Medicine, University of Porto (FMUP) & I3S-Instituto de Investigação e Inovação em Saúde, Portugal

Pedro Correa de Sampaio, CEO, Neobe Therapeutics, United Kingdom

Ana Paula Moreira, Nurse, IPO Porto, Portugal

Paula Monteiro, Director of the Anatomic Pathology Department, IPO Porto, Portugal

Martina Antošová, Head of Department of Biomedical Research and Clinical Studies, University Hospital Martin, Slovakia

Isabel Veiga, Geneticista laboratorial, IPO Porto, Portugal

Mireia Castillo-Martin, Head of the Molecular and Experimental Pathology Lab, Champalimaud Centre for the Unknown, Portugal

Olga Sousa, Medical Doctor, IPO Porto, Portugal

Sara Jácome, Nurse / Master Student, ICBAS / Hospital CUF Porto, Portugal

Raquel Lopes, PhD Student, Champalimaud Foundation, Portugal

Maria Irene Paula, Nuclear Medicine Technologist Coordinator, IPO Porto, Portugal

Dulce Maria Gonçalves Pereira, Enfermeira Especialista Médico Cirúrgica, Hospital São João, Portugal

Camila Coutinho, Diretora do Serviço de Oncologia Médica, Hospital Senhora da Oliveira - Guimarães, Portugal

Vasco Varela, CEO, PETSys Electronics - Medical PET Detectors, SA, Portugal

Marija Garcia, Grants Officer, Instituto de Medicina Molecular João Lobo Antunes, Portugal

Clarinda Fernanda da Silva Festas, Diretor, Escola Superior de Saúde Fernando Pessoa (ESS-FP), Portugal

Filipa Carvalho, Médica, ACeS Ave - Famalicão - USF S. Miguel o Anjo, Portugal

João Moreira Pinto, Chief Medical Officer, Hospital-Escola da Universidade do Porto, Portugal

Pedro Silva, Técnico de Radioterapia, IPO Porto, Portugal

Alexandra Moreira, Research Group Leader, IBMC/i3S, Portugal

Susana Rute Ferreira Gregório, Head Nurse Director, Hospital- Escola Universidade Fernando Pessoa, Portugal

Feliz Ribeiro Gouveia, Professor, Universidade Fernando Pessoa, Portugal

Liliana Manuela Barbosa Soares, Enfermeira, ACES Baixo Tamega, Portugal

Susana Maria Oliveira Dias, Assistente Hospitalar - Radiologia, IPO Porto, Portugal

Joana Paredes, Principal Investigator, Institute for Investigation and Innovation In Health (I3S), Portugal

Danny Van Roijen, Digital Health Director, COCIR, Belgium

José M Calheiros, FP-I3ID, Director, Universidade Fernando Pessoa, Porto, Portugal

Hugo André Costa, Board Member, Agencia Espacial Portuguesa - Portugal Space, Portugal

Gustavo Guerra Jacob, Cirurgião Oncológico, Oncoclínicas do Brasil, Brasil

Ana Sofia Silva, Técnico Superior, IPO Porto, Portugal

Rita Ribeiro da Silva, MD, PhD, IPO Porto, Portugal

Diogo Silva, Médico, Hospital Pedro Hispano, Portugal

Silvia Costa, Lecturer in Physical Activity and Public Health, Loughborough University, United Kingdom

Vítor Gaspar, Junior researcher, University of Aveiro, Portugal

Bruno Vaz, Diretor Área de Negócio Diagnóstico, Quilaban SA, Portugal

Ana Luísa Pereira Teixeira, Junior Researcher, IPO Porto, Portugal

Leonardo Maia Moço, Médico Interno de Formação Geral, Centro Hospitalar Universitário do Algarve - Unidade Hospitalar de Portimão, Portugal

Bernardo Luis Freire Albuquerque Carvalho Machado, Key Account Seieculust, Corza Meducal, Portugal

Hugo Manuel Lopes de Sousa, Investigador, IPO Porto, Portugal

José Fernando A. Cruz, Professor Associado Aposentado, Universidade do Minho, Portugal

Maria Pedro de Pinho Ferreira da Silva, Portugal

Maria Rosa Guedes Matos Correia, Doente oncológica, IPO Porto, Portugal

Anton Ussi, Operations and Finance Director, European Research Infrastructure for Translational Medicine (EATRIS), Portugal

Toni Andreu, Scientific Director, European Research Infrastructure for Translational Medicine (EATRIS), Portugal

Sara Ramos, FAS, Ilc, Portugal

Filipa Valente, Real World Evidence Manager, AstraZeneca, Portugal

Rita Pinto, Engenheira, Portugal

Elisabete Fernandes, Information and Science Management, FP-I3ID, Universidade Fernando Pessoa, Portugal

Sofia Moreira, IPO Porto, Portugal

Jacques Demotes, Director, ECRIN, Portugal

Prof. Jens K. Habermann, Director General, BBMRI-ERIC (Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium), Österreich

Andreia Capela, Medical Doctor-Oncology, Centro Hospitalar Vila Nova de Gaia /Espinho, Portugal

Inês Carvalho, Clinical Trials Study Coordinator, IPO Porto, Portugal

Ana Sofia Marques, Portugal

Maria Inês Baldaque Barbosa, Directora do Serviço de Virologia, IPO Porti, Portugal

Manuel Ottaviano, Researcher, Universidad Politecnica de Madrid, Spain

Nuno Rodrigues dos Santos, Assistant Professor in Research, i3S Instituto de Investigação e Inovação em Saúde, Portugal

Samantha Brunella Medugno, news reading - citizen, Private non enroled - ExStudent Jurist explicit declarer of perduring non-political activity repretation, says abstention from any activities, Italy

Celso Reis, Principal Research; Group Leader, i3S/Ipatimup University of Porto, Portugal

Andreia Rosário, Research Technician, IPATIMUP, Portugal

Ana Magalhães, Researcher, I3S, Portugal

Helena Pópulo, Researcher, I3S, Portugal

Patrícia Alexandra Barreiras Carneiro, Researcher, I3S, Portugal

Helder Maiato, Coordinating Investigator, I3S, Portugal

Paula Maria Sequeira Tamagninil Barbosa Oxelfelt, Associate Professor, I3S, Portugal

Joana Figueiredo, Junior Researcher, I3S, Portugal

Maria Manuela Ferreira Brás, Research Assistant, , I3S, Portugal

Ariana, Junior Researcher, I3S, Portugal

Sofia Santos, Junior Researcher, I3S, Portugal

Sofia Santos, Post-Doctoral Researcher, I3S, Portugal

Bernard Nunes de Almeida Orr, Research Associate, I3S, Portugal

Marta Luisa Sousa Dias Alves da Silva, Researcher, I3s/ IBMC, Portugal

Fátima Martel, Full Professor, Faculty of Medicine of Porto, Portugal

Raquel Soares, Full Professor; Group leader, Faculty of Medicine, University of Porto; i3S, Institute of Research and Innovation in Health, Portugal

Isabel Martins Silva, Head of Communications | Corporate Social Responsibility, UPTEC - Science and Technology Park of University of Porto, Portugal

Paula Soares, Researcher, IPATIMUP/I3S, Portugal

Natália Cruz-Martins, Professor, Faculty of Medicine, University of Porto, Portugal

Cristina Potier, Directora Geral, Fundação Rui Osório de Castro, Portugal

Vítor Costa, Associate Professor, University of Porto, Portugal

Joana Ribeiro, Project Manager, ITQB NOVA, Portugal

Catarina Rodrigues, PhD student /MD, IPO Porto, Portugal

Hugo Osorio, Researcher, i3S/IPATIMUP, Portugal

Sophie Beaupère, Chief Executive Officer, Unicancer, France

Ana Rita Ribeiro de Almeida Castanheira, Presidente do Conselho de Administração, Centro Hospitalar de Trás-os-Montes e Alto Douro, Portugal

Ondrej Slaby, Professor, University Hospital Brno, Czech Republic

Prof. Simona Kustec, Minister, Ministry of Education, Science and Sport, Slovenia

Anja Karliczek, Federal Minister, Federal Ministry of Education and Research, Germany

Carla Paixão, NVS, Portugal

Jane Smith, Chief Executive Officer, European Association for Cancer Research, United Kingdom

Ricardo Paulo Senra Monteiro, Research Fellow, Institute for Molecular and Cell Biology, Portugal



2021PORTUGAL.EU